A series of SPMVIII analogs were synthesized to investigate the effect of the amino acid moiety on the antitumor activity. The L-threonine analog and the glycylglycine analog of SPMVIII showed much higher cytotoxity to P388 murine leukemia cells (IC50 5.8 nM and 0.1 1 nM, respectively) than SPMVIII (IC50 25 nM). However, replacement of the glycine moiety with other amino acids greatly reduced the antitumor activity against COL-1humancolon cancer xenograft model. This study indicated that the glycine moiety of SPMVIII is crucial for the antitumor effect.
Synthesis and Antitumor Activities of Glycine-exchanged Analogs of Spicamycin
A series of SPMVIII analogs were synthesized to investigate the effect of the amino acid moiety on the antitumor activity. The L-threonine analog and the glycylglycine analog of SPMVIII showed much higher cytotoxity to P388 murine leukemia cells (IC50 5.8 nM and 0.1 1 nM, respectively) than SPMVIII (IC50 25 nM). However, replacement of the glycine moiety with other amino acids greatly reduced the antitumor activity against COL-1humancolon cancer xenograft model. This study indicated that the glycine moiety of SPMVIII is crucial for the antitumor effect.
Spicamycin (1)1>2) was isolated from the culture broth of a Streptomyces alanosinicus 879-MT3as a differentiation inducer of mouse myeloid leukemia cells (Ml) and human promyelocytic leukemia cells . And it showed antitumor activity against P388 leukemia in mice. Spicamycin (1) is a mixture of several related components that differ only in their alkylacyl moieties (C12~C18), and it showed potent antitumor activity against human breast cancer MX-1and human stomach cancer SC-9 in the human tumor xenograft model3). In the mixture of spicamycin, the dodecanoyl compound (SPM VIII, 2, Fig. 1 ) exhibited the highest antitumor activity3'40. Other fatty acid analogs of spicamycin were synthesized and evaluated, and KRN5500(3) showed marked activity against human xenograft models5)6). The purpose of the present study was to synthesize a series of spicamycin analogs to investigate the effect of the amino acid moiety on the antitumor activity with a hope of identifying a derivative having an increased potency. This report describes syntheses and antitumor activities of the glycine-modified analogs of SPMVIII.
Chemi stry Spicamycin amino nucleoside (SAN, 4, 4-deoxy-L-g/>^m?-/^L-wtf/2«0-heptopyranosylammo)-9iJ-purine7)) was prepared by the hydrolysis of spicamycin (1) with 10%HC1 in methanol under reflux for 24hours3>5).
The dodecanoyl amino acids derivatives (6a~6e, 6g, 6h) were obtained from dodecanoylchloride and appropriate amino acids3). In the case of the L-lysine derivative, we used 7V£-Cbz-L-lysine for synthesis. The L-methionine analogs were partially racemized under this condition. Treatment of dodecanoyl amino acids with 7V-hydroxysuccinimide (HOSu) and dicyclohexylcarbodiimide (DCC) in dimethylformamide (DMF) gave active esters, which were allowed to react with SAN(4) in DMF in the presence of triethylamine to give glycine exchanged analogs (7a~7e, 7g, 7h). The glycylglycine derivative (7i) was obtained from dodecanoylglycine3) and SAN-Gly (5) by the active ester method using HOSu and DCC. Protecting group of 7V£-Cbz-L-lysine was treated with HBr in AcOHto give (7f). The structure of the analogs, 7a~7i are shown in Table 1 .
Results and Discussion
Nine spicamycin derivatives were evaluated for in vitro (1) However, the jS-alanyl analog (7d) reduced the cytotoxicity. The in vivo activity of L-alanyl (7c) and jS-alanyl (7d) derivatives showed no therapeutic effect but toxicity. The basic (L-lysyl) amino acid derivative (7f) and charge protected one (7e) showed less cytotoxicity. Replacement of glycine moiety with amino acid containing hydroxyl Fragments of COL-1 humancolon cancer were implanted subcutaneously into athymic nude mice. Whenthe tumor size reached 100~300 mm3,glycine exchanged spicamycin analogs were given iv daily for five days.
a Therapeutic index (T.I.)=maximum tolerated dose/ minimum effective dose. b One or more animals died. c Results were expressed as the values of maximum tumor growth inhibition rate (T.G.I. R) through the experimental span; five mice per group. The bold value was evaluated as "effective" according to the criteria described in "Experimental".
group caused enhanced cytotoxicity. The IC50 value of the L-serine derivative (7g) was equal to that of SPM VIII and the L-threonine derivative (7h) was effective as SPMVIII at a concentration 4 times lower than SPM VIII. In spite of the potent cytotoxicity, these derivatives did not show the sufficient activity in vivo. The cyto-toxicity of glycylglycine analog (7i) was shown to be 20-fold more active than SPM VIII. However, the glycylglycine derivative (7i) exhibited the tumor inhibitory effect in vivo only at 3 mg/day. The therapeutic index of (7i) was inferior to that of SPMVIII. None of these amino acid analogs showed better in vivo activity than SPMVIII. Thus, glycine is the best amino acid for antitumor activity in this series.
In the study of the mode of action of spicamycin analog6) (KRN5500), we reported that KRN5500 inhibit the protein synthesis in tumor cell. In addition, we showed that KRN5500 metabolite, SAN-Gly, inhibited the protein synthesis in reticulocyte lysate, whereas KRN5500 did not. These findings suggested that the amide bond between fatty acid and glycine moieties would be hydrolyzed with the cellular membrane enzyme to generate the SAN-Gly. SAN-Gly inhibit the protein synthesis of tumor cell and show the cytotoxic effect. Since these analogs showed no antitumor activity, corresponding intracelluar metabolites might be less active than SAN-Gly against the inhibition of protein synthesis. Although 7g, 7h and 7i had potent cytotoxicities, these compounds showed considerable reductions in antitumor activity against COL-1 human xenograft model. It is speculated that potent cytotoxicities of these compoundsinduce reductions of in vivo activity, which are also observed in the analog study of fatty acid moiety3).
E xpe rime nt al General MP's were determined with a Yanagimoto micro hot-stage apparatus and not corrected. Specific rotations were obtained with a Jasco DIP-140 spectropolarimeter. IR spectra were recorded on a Jasco A-3 spectrophotometer. UVspectra were recorded on a Hitachi U-3200 in MeOH solution and NMRspectra on a Jeol GX-500 spectrometer. The FDmass spectra were obtained with a Hitachi M80mass spectrometer.
Spicamycin Amino Nucleoside (4) A solutionof1.0g of1 in 100ml of10% HC1-MeOH was allowed to stir under reflux for 24 hours. The solution was concentrated in vacuo to the minimum volume and diethyl ether was added. The resulting precipitate was centrifuged and washed with diethylether to give a white powder. This powder was dissolved in water and washed with w-butanol. The aqueous layer was neutralized with silver carbonate and the formed precipitate was filtered off. The filtrate was concentrated and the residue was further purified by column chromatography on silicagel (CHCl3- Preparation of compounds, 7b, 7c, 7d, 7e, 7g and 7h followed a similar process as discribed above using appropriate aminoacids. 6-[4-Deoxy-4-(dodecanoyl-glycylglycyl)amino-L-g/^-cer6>-/^L-mflm2o-heptopyrano sylamino] -9/f-purine (7i) This compound was obtained from SAN-Gly (5)5) 
6-[4-Deoxy
-9//-purine (7f)
To a chilled solution of20% HBr in AcOH(5ml) was added 7e (1 15 (100units/ml, Meiji Seika Kaisha Ltd., Tokyo, Japan) and streptomycin (100 /ig/ml, Meiji Seika Kaisha Ltd., Tokyo, Japan), and 2-mercaptoethanol (5 x 10~5m). In Vivo Antitumor Activity For all experiments, 6~8-week-old female, athymic nude mice (BALB/c nu/nu Sic, Japan SLC Inc., Shizuoka, Japan) were used. The animals were kept under specific pathogen free conditions using laminar air flow racks and were fed sterile food and water ad libitum.
Humancolon cancer COL-1 were kindly supplied by the Central Institute for Experimental Animals, Kanagawa, Japan, and maintained in athymic nude mice. Chemotherapuetic experiments were performed as de-scribed by Inaba et al8). Fragments of xenografts were implanted sc into the right subaxillary region of athymic nude mice. Whenthe tumors had grown to a palpable size (100~300mm3), the mice were randomly allocated to several experimental groups consisting of five animals each and spicamycin derivatives at each dose were given intravenously by daily injection for five days. Control mice were given 10ml/kg vehicle. From the start of the injections, the tumor volume (V) was calculated once or twice a week for 3weeks as follows; V=abc/2 , where a and b are the long and short diameter and c is the height of the tumor mass in mm.Relative tumor volume (RV) is expressed as RV= Vn/V0, where Vn is the tumor volume on day n and Vo is the initial tumor volume at the time treatment was commenced (day 1). T.G.I.R. was determined as follows; T.G.I.R. =(1 -T/C) x 100 where T is the mean of RVin treated mice and C is the mean of RVin control mice. Evaluation as "effective" was based on the maximum T.G. 
